Dear Editor

Richtsmeier, William J.; Rothman, Warren

doi:10.1288/00005537-198906000-00021

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference may reflect the exclusion of approximately one-third of the patients screened for the study because their gastroesophageal reflux improved with anti-reflux measures and medications. In fact, several observational studies have described reversal of carcinoma-in situ with treatment of reflux (25, 26) as well as regression of premalignant changes and decreased incidence of cancer recurrences after initiating H2-receptor antagonists (27), and a meta-analysis suggests that GERD may be a factor in the pathogenesis of laryngeal cancer. (28) Our previous trial could have been biased by including patients with lesions responsive to gastroesophageal-reflux control alone.…”

Section: Discussionmentioning

confidence: 99%

Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients

Papadimitrakopoulou

Izzo

Liu

et al. 2009

Cancer Prevention Research

View full text Add to dashboard Cite

In a previous trial, we found that combined 13-cis retinoic acid (13-cRA), interferon-α and α-tocopherol more effectively reversed advanced premalignant lesions of the larynx than of the oral cavity and that cyclin D1 (CD1)G/A870 single nucleotide polymorphism correlated with cancer risk. We conducted the present trial primarily to confirm the clinical activity of the combination in advanced laryngeal premalignancy and to confirm and extend our findings on CD1, both genotype and protein expression, in association with cancer risk in this setting. Twenty-seven moderate-to-severe laryngeal dysplasia patients underwent induction with combined 13-cRA daily, α-interferon twice weekly, and α-tocopherol daily for one year; 14 non-progressing patients then were randomized to maintenance fenretinide or placebo for two years. During induction, 2 patients had pathological complete responses, 6 had partial responses (30% overall response rate), and 5 developed laryngeal cancer. There were no significant differences between maintenance fenretinide and placebo in response or cancer rates. Ten patients developed cancer overall. Twenty-four patients were evaluated for the CD1 G/A870 genotype, and 23 for pre- and post-treatment CD1 protein expression. Consistent with our earlier report, shorter cancer-free survival was associated with the CD1 AA/AG genotype (p = 0.05). Extending our earlier work, high CD1 expression was associated with worse cancer-free survival overall (p= 0.04) and within each CD1 genotype group. These findings support CD1 genotype and protein expression as important risk markers for laryngeal cancer and suggest future trials targeting upstream regulators of CD1 transcription.

show abstract

Section: Discussionmentioning

confidence: 99%

Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients

Papadimitrakopoulou

Izzo

Liu

et al. 2009

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

Laryngopharyngeal Manifestations of Gastroesophageal Reflux Disease

Olson

1991

Otolaryngologic Clinics of North America

View full text Add to dashboard Cite

Role of gastroesophageal reflux disease in patients with cervical symptoms

Rival¹,

Wong²,

Mendelsohn³

et al. 1995

Otolaryngology - Head and Neck Surgery

View full text Add to dashboard Cite

Otolaryngologists commonly see patients with various nonspecific upper aerodigestive or "cervical" symptoms. The relationship between gastroesophageal reflux disease and these symptoms has been studied but remains unclear. We reviewed the records of 216 patients with various cervical symptoms. Each patient underwent a uniform investigation that included barium swallow, esophageal manometry, acid stimulation testing, and esophagoscopy with distal biopsy. Patients were treated with a combination of a histamine H2 blocker or omeprazole and a prokinetic agent. Follow-up was obtained in 194 patients. Overall, evidence of gastroesophageal reflux disease was detected in 73% of patients. Complete resolution or improvement of symptoms was seen in 84% of patients with treatment. We believe gastroesophageal reflux disease is an important factor in the cause of cervical problems.

show abstract

Dear Editor

Cited by 3 publications

References 2 publications

Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients

Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients

Laryngopharyngeal Manifestations of Gastroesophageal Reflux Disease

Role of gastroesophageal reflux disease in patients with cervical symptoms

Contact Info

Product

Resources

About